Post-stripping sclerodermiform dermatitis.
BACKGROUND
Cutaneous sclerosis, a process that results in hardening of the skin, is the hallmark of scleroderma and sclerodermoid disorders. Cutaneous sclerosis is usually classified as secondary or primary, depending on the presence or absence of underlying diseases. Primary cutaneous sclerosis is a feature of idiopathic inflammatory processes that are often associated with autoimmune disorders, whereas secondary cutaneous sclerosis arises in the context of many pathological processes of varying causes, including chronic graft-vs-host disease, defined metabolic or genetic disorders, and exposure to certain infectious organisms, drugs, or chemicals.


METHODS
Three patients had localized cutaneous sclerosis overlying the site of a surgically removed (stripped) great saphenous vein. In all 3 patients, lesions were clinically characterized by multiple hypopigmented and indurated plaques distributed linearly along the path of the preexisting vein. Extensive history, physical examination, and diagnostic tests did not reveal known predisposing factors for cutaneous sclerosis.


CONCLUSIONS
Although the observed association of sclerodermiform dermatitis and venous stripping in these 3 patients does not imply a causal relationship, the absence of other identifiable predisposing factors and the striking linear distribution of the cutaneous lesions along the path of the preexisting vein are suggestive. This poststripping sclerodermiform dermatitis may be a rare late complication of saphenous vein stripping.
French
L E
LE
Department Hospitalo-Universitaire Romand de Dermatologie Geneva/Lausanne, Geneva, Switzerland. french@cmu.unige.ch
Braun
R
R
Masouyé
I
I
Ramelet
A A
AA
Humbert
P G
PG
Saurat
J H
JH
D000328:Adult; D005260:Female; D006801:Humans; D017496:Hypopigmentation / Q000209:etiology; D018459:Lichen Sclerosus et Atrophicus / Q000150:complications; D008297:Male; D008875:Middle Aged; D015434:Panniculitis / Q000209:etiology; D000077423:Polidocanol; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011183:Postoperative Complications; D012307:Risk Factors; D012501:Saphenous Vein / Q000601:surgery*; D012594:Scleroderma, Localized / Q000209:etiology*; D012597:Sclerosing Solutions / Q000627:therapeutic use; D015911:Sclerotherapy; D014648:Varicose Veins / Q000601:surgery / Q000628:therapy
D012597:Sclerosing Solutions; D000077423:Polidocanol; D011092:Polyethylene Glycols